Prostate Cell News Volume 11.05 | Feb 14 2020

TOP STORY

Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer

The prostate cancer multistage murine model TRAMP and TRAMP-derived cells have been used to extensively characterize in vitro and in vivo the response and resistance to enzalutamide. [Cancer Res] Abstract

(Ranked by impact factor of the journal)

Methiothepin Mesylate Causes Apoptosis of Human Prostate Cancer Cells by Mediating Oxidative Stress and Mitochondrial Dysfunction

Scientists verified apoptotic cell death in prostate cancer cell lines after treatment with methiothepin mesylate, an antagonist for serotonin receptor 5-HT1. [Free Radic Biol Med] Abstract | Graphical Abstract

Luminescent Pt^II and Pt^IV Platinacycles with Anti-Cancer Activity against Multiplatinum-Resistant Metastatic CRC and CRPC Cell Models

Researchers report the synthesis, reduction studies, and luminescent properties of a series of cyclometallated Pt^IV compounds derived from amine-imine ligands against multiplatinum-resistant colorectal cancer (CRC) and castration-resistant prostate cancer (CRPC) metastatic cell lines. [Chemistry] Abstract

Isorhamnetin Inhibited the Proliferation and Metastasis of Androgen-Independent Prostate Cancer Cells by Targeting the Mitochondrion-Dependent Intrinsic Apoptotic and PI3K/Akt/mTOR Pathway

Treatment with Isorhamnetin significantly inhibited cell growth and induced lactate dehydrogenase release of androgen-independent prostate cancer cells, but exhibited almost no toxicity effect on androgen-dependent LNCaP prostate cancer cell line or normal human prostate epithelial PrEC cells. [Biosci Rep] Abstract

Could the Kinetin Riboside Be Used to Inhibit Human Prostate Cell Epithelial-Mesenchymal Transition?

Kinetin riboside inhibited the growth of human prostate cancer cells, but also, to a small extent, of normal cells. This effect depended on the type of the cells and their androgen sensitivity. [Med Oncol] Abstract

Silver Nanoparticles Regulate Autophagy through Lysosome Injury and Cell Hypoxia in Prostate Cancer Cells

Investigators clarified the distinct mechanisms of silver nanoparticles for the regulation of autophagy in prostate cancer PC-3 cells under sublethal exposure. [J Biochem Mol Toxicol] Abstract

A Novel Pregnene Analogs: Synthesis, Cytotoxicity on Prostate Cancer of PC-3 and LNCPa-AI Cells and In Silico Molecular Docking Study

The in vitro cytotoxic activities of selected synthesized steroids against two human prostate cancer cell lines were evaluated by MTT assay. [Mol Divers] Abstract | Graphical Abstract

Targeted Alpha Therapy with Astatine-211-Labeled Anti-PSCA A11 Minibody Shows Antitumor Efficacy in Prostate Cancer Xenografts and Bone Microtumors

PC3-PSCA cells were implanted subcutaneously and intratibially in nude mice. Efficacy of α-RIT was studied on subcutaneously macrotumors and on intratibially microtumors by tumor-volume measurements. [EJNMMI Res] Full Article

MicroRNA Let-7b Inhibits Proliferation and Induces Apoptosis of Castration-Resistant Prostate Cancer Cells by Blocking the Ras/Rho Signaling Pathway via NRAS

Overexpression of let-7b or silencing of neuroblastoma RAS viral oncogene homolog (NRAS) repressed C4-2 cell proliferation and invasion in vitro and tumor growth in vivo as well as induced C4-2 cell apoptosis in vitro through the blockage of the Ras/Rho signaling pathway. [Clin Transl Sci] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Focal Therapy for Localized Prostate Cancer in the Era of Routine Multi-Parametric MRI

The widespread adoption of prostate mpMRI has led to improved disease localization, enabling the performance of focal therapy as a viable treatment strategy for men with low volume intermediate-risk prostate cancer. [Prostate Cancer Prostatic Dis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

XTANDI^® (Enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase III PROSPER Trial of Patients with nmCRPC

Astellas Pharma Inc. announced results of the final overall survival analysis from the Phase III PROSPER trial, which evaluated XTANDI^® plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). [Astellas Pharma Inc.] Press Release

Advaxis Announces Updated Survival Data in Phase I/II ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

Advaxis, Inc. announced updated results from the combination arm of KEYNOTE-46 (Part B), the company’s ongoing Phase I/II study investigating ADXS-PSA with KEYTRUDA^® in patients with metastatic, castrate-resistant prostate cancer (mCRPC). [Advaxis, Inc. (GlobalNewswire, Inc.)] Press Release

Popular Preprint Servers Face Closure Because of Money Troubles

The rise of preprint repositories has helped scientists worldwide to share results and get feedback quickly. But several platforms that serve researchers in emerging economies are struggling to raise money to stay afloat. Repositories like INA-Rxiv and IndiaRxiv boost regional science, but finding cash to run them is proving difficult. [Nature News] Editorial

FDA Now Allows Certain Lab Animals to Be Retired and Adopted

The US Food and Drug Administration will now permit certain animals used in experiments to retire and be adopted rather than face euthanasia, according to internal documents reviewed by The Hill. Although the policy changed in November, there have not been any public statements from the agency. [The Scientist] Editorial

NEW American Association for Cancer Research (AACR) Annual Meeting 2020
April 24-29, 2020
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Studentship – Stress Signaling and Prostate Cancer (University of Oslo)

Postdoctoral Research Associate – Cancer Development (University of Cambridge)

Postdoctoral Fellow – Prostate Tumorigenesis (University of Cincinnati)

Postdoctoral Fellow – RNA Splicing in Cancer (The University of Texas MD Anderson Cancer Center)

Postdoctoral Position – Organoid Models of Prostate Cancer (University of Freiburg)

Research Fellow – Anti-Cancer Therapy (Mayo Clinic)

Postdoctoral Position – Cancer Cell Competition (Albert Einstein College of Medicine)

Postdoctoral Fellow – Cancer Biology (City of Hope)

Postdoctoral Fellow – Translational Cancer Research (University of New Mexico)

Postdoctoral Researcher – Chromatin Structures in Cancer Cell States (Medical University of Gdańsk)

Tenure-Track Faculty Scientist Position – Radiation Oncology (New York University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.